Marshall Wace’s AbCellera Biologics ABCL Stock Holding History

Marshall Wace’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.26M	Buy	+359,683	New	+$1.29M	﹤0.01%	2022
2025 Q4	–	Sell	-47,480	Closed	-$239K	–	2900
2025 Q3	$239K	Hold	47,480	–	–	﹤0.01%	2517
2025 Q2	$163K	Hold	47,480	–	–	﹤0.01%	2486
2025 Q1	$106K	Buy	+47,480	New	+$136K	﹤0.01%	2495
2023 Q1	–	Sell	-97,600	Closed	-$989K	–	2587
2022 Q4	$989K	Sell	97,600 -256,797	-72%	-$2.97M	﹤0.01%	2100
2022 Q3	$3.5M	Sell	354,397 -159,313	-31%	-$1.75M	0.01%	1641
2022 Q2	$5.47M	Buy	+513,710	New	+$4.35M	0.01%	1271
2021 Q4	–	Sell	-338,120	Closed	-$6.78M	–	3809
2021 Q3	$6.78M	Buy	338,120 +64,841	+24%	+$1.15M	0.03%	780
2021 Q2	$6.01M	Buy	273,279 +222,638	+440%	+$6.14M	0.03%	739
2021 Q1	$1.72M	Sell	50,641 -461,769	-90%	-$18.4M	0.01%	1398
2020 Q4	$20.6M	Buy	+512,410	New	+$23.4M	0.11%	186

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace's ABCL Position: Q1 2026 in Review

Marshall Wace opened a new position in AbCellera Biologics (ABCL) in Q1 2026: 359,683 shares worth $1.26M. The stake represents ﹤0.01% of the portfolio and ranks #2022 among its holdings. This is a return to the name: Marshall Wace previously reported a position in ABCL as recently as Q3 2025.

Marshall Wace first reported a position in ABCL in Q4 2020 and has held it in 11 quarters since. The position peaked at $20.6M in Q4 2020. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Marshall Wace held 359,683 shares of AbCellera Biologics worth $1.26M as of Q1 2026.
AbCellera Biologics was a new Marshall Wace position in Q1 2026.
AbCellera Biologics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2022 holding.
Marshall Wace first reported a position in AbCellera Biologics in Q4 2020 and has held it in 11 quarters since.
Marshall Wace's AbCellera Biologics position peaked at $20.6M in Q4 2020.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.